MK-4409
Non-covalent oxazole FAAH inhibitor (IC50 11 nM) made by Merck and studied in rat pain models; no commercialisation found.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₂H₁₇ClFN₃O₂S
CAS 1207745-58-1
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 441.90 g/mol
Updated on
In plain terms
MK-4409 blocks the enzyme that destroys anandamide, which raises the endocannabinoids the body makes naturally. Made by Merck, it reduced pain hypersensitivity in rat models. It was not marketed and no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to MK-4409: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of MK-4409.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorIC50 = 11 nM · human66 out of 100
Chobanian et al., ACS Med Chem Lett 2014 (full text PMC4060928, table 1) (new tab) · human FAAH lysate, IC50 11 nM (rat: 11 nM); non-covalent, reversible inhibition; table 1 of the article
- hERG channel ([35S]MK-499 binding)Binding (function not established)Ki = 1.3 µM32 out of 100
Chobanian et al., ACS Med Chem Lett 2014 (full text PMC4060928, table 1) (new tab) · [35S]MK-499 displacement; off-target measured in table 1; functional effect not established
Pharmacology
MK-4409 is a fatty acid amide hydrolase (FAAH) inhibitor designed by Merck Research Laboratories to act in pain models by an indirect route: preventing the breakdown of anandamide rather than directly activating CB1. Chobanian and colleagues describe in 2014 the optimisation of a screening hit (a pyrazole) into a non-covalent, reversible oxazole compound: IC50 11 nM on human and rat FAAH, lower hERG binding (Ki 1,254 nM) and no notable inhibition of the vesicular monoamine transporter (EC50 above 20,000 nM) that the pyrazole analogues showed. In rats, given orally, it reduced complete Freund's adjuvant-induced allodynia at 10 and 30 mg/kg (49 to 51% then 70 to 71% reversal) to a level comparable to naproxen and, in a spinal nerve ligation model, produced about 50% reversal of allodynia at 3 mg/kg with no effect on the rota-rod up to 100 mg/kg, where URB597 needed 21 mg/kg (Chobanian et al. 2014). The authors conclude that the pharmacokinetic parameters supported development of a once-daily compound in humans; no data in humans were found. For class context, a phase 1 study of another FAAH inhibitor, BIA 10-2474, led to the death of one volunteer and neurological symptoms in four others; the cause is unknown and a hypothesis of inhibition of several lipases not targeted by a selective FAAH inhibitor has been put forward (van Esbroeck et al. 2017). Nothing of the kind is reported for MK-4409.
Key sources.
- Chobanian HR et al. Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain. ACS Med Chem Lett, 2014 (new tab)PMID 24944750
- van Esbroeck ACM et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017 (new tab)PMID 28596366
- PubChem, MK-4409, CID 53341130 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It comes from a medicinal chemistry programme at Merck Research Laboratories (Chobanian et al. 2014); no commercialisation was found.
Origin
Research tool
No biological pathway: MK-4409 is a synthetic compound, an oxazole substituted with a pyridine thioether, a pyridine bearing a tertiary alcohol and a fluorophenyl, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: MK-4409 is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this oxazole falls within none of the generic families of that list. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Chobanian HR et al. Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain. ACS Med Chem Lett, 2014 (new tab)PMID 24944750
- van Esbroeck ACM et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017 (new tab)PMID 28596366
- PubChem, MK-4409, CID 53341130 (identifiers and properties) (new tab)
Identifiers
Names
- IUPAC name
- 2-[5-[5-[(5-chloro-2-pyridinyl)sulfanyl]-2-(4-fluorophenyl)-1,3-oxazol-4-yl]-2-pyridinyl]propan-2-ol
- Other names
- MK4409 · MK 4409
Identifiers
- Formula
- C₂₂H₁₇ClFN₃O₂S
- CAS
- 1207745-58-1
- PubChem CID
- 53341130(new tab)
- InChIKey
- DBZMCSVIITXLCC-UHFFFAOYSA-N
- SMILES
- CC(C)
(C1= NC= C(C= C1) C2= C(OC(= N2) C3= CC= C(C= C3) F) SC4= NC= C(C= C4) Cl) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.